From the release it sounds like the first trial only enrolled non-ciorrhotics w high baseline VL, so the 95% SVR has to be taken in that context. Not sure about the randomized portion, but the 98% here helps compete w GILD (GILD had 100% SVR in a somewhat smaller trial) I don't think the cirrhotic data is competitive w GILD though
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.